News | October 08, 2007

FDA Clears Endovascular System For Clot Removal

October 9, 2007 - OmniSonics Medical Technologies Inc. has received clearance from the FDA to market its catheter based OmniWave Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature, as the company targets the deep vein thrombosis (DVT) market.

The OmniWave Endovascular System has a minimally invasive catheter-based technology that delivers low-power, transverse ultrasonic energy designed to remove thrombus quickly, safely and effectively.

The device treats DVT, which affects approximately 2 million people in the U.S. every year, and acute limb ischemia, which affects over 250,000 people in the U.S. every year.

For more information:

Related Content

Illustration of the EkoSonic catheter aiding drug-dispersion in a DVT clot. Catheter directed thrombolysis of deep vein thrombosis.

Illustration of the EkoSonic catheter aiding drug-dispersion in a DVT clot.

Feature | Deep Vein Thrombosis (DVT) | February 16, 2018 | Sanjay Pandya, M.D.
There are few downsides to using tibial venous access to treat...
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis (DVT) | July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
NICE, U.K., edoxaban, Lixiana, VTE, venous thromboembolism, deep vein thrombosis, pulmonary embolism
News | Deep Vein Thrombosis (DVT) | August 12, 2015
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help patients suffering...
Overlay Init